Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Science Advances (2023) Vol. 9, Iss. 13
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
ACS Central Science (2023) Vol. 9, Iss. 8, pp. 1658-1669
Open Access | Times Cited: 204
SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 678
Open Access | Times Cited: 102
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
Virus Evolution (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 69
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 67
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
Chong Huang, Huiping Shuai, Jingxin Qiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 49
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 46
Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6
Taha Y. Taha, Irene P. Chen, Jennifer M. Hayashi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 44
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
Maki Kiso, Seiya Yamayoshi, Shun Iida, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 17
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 14
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
Seyed Arad Moghadasi, Rayhan G. Biswas, Daniel A. Harki, et al.
npj Antimicrobials and Resistance (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 30
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
Maki Kiso, Yuri Furusawa, Ryuta Uraki, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 263-266
Open Access | Times Cited: 25
Dynamical Nonequilibrium Molecular Dynamics Simulations Identify Allosteric Sites and Positions Associated with Drug Resistance in the SARS-CoV-2 Main Protease
H. T. Henry Chan, A. Sofia F. Oliveira, Christopher J. Schofield, et al.
JACS Au (2023) Vol. 3, Iss. 6, pp. 1767-1774
Open Access | Times Cited: 25
Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
Julia M. Flynn, Qiu Yu J. Huang, Sarah N. Zvornicanin, et al.
ACS Infectious Diseases (2023) Vol. 9, Iss. 7, pp. 1372-1386
Open Access | Times Cited: 23
Structural biology of SARS-CoV-2 Mpro and drug discovery
Yinkai Duan, Haofeng Wang, Zhenghong Yuan, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102667-102667
Closed Access | Times Cited: 22
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Xiong Xie, Qiaoshuai Lan, Jinyi Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Lijing Zhang, Xuping Xie, Hannan Luo, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Clinical, Genomic, and Immunological Characterization of RSV Surge in Sydney, Australia, 2022
Gregory J. Walker, Charles S. P. Foster, Andrea Sevendal, et al.
PEDIATRICS (2024)
Open Access | Times Cited: 10
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Yuao Zhu, Irina Yurgelonis, Stephen Noell, et al.
Science Advances (2024) Vol. 10, Iss. 30
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top